Seminars in Oncology
Volume 33 , Pages 29-35 , April 2006

Strategies in the Management of Alemtuzumab-Related Side Effects

References 

  1. Rai KR , Peterson BL , Appelbaum FR , et al.   Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia . N Engl J Med . 2000;343:1750–1757
  2. Morrison VA , Rai KR , Peterson BL , et al.   Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia (Intergroup Study Cancer and Leukemia Group B 9011) . J Clin Oncol . 2001;19:3611–3621
  3. Robak T , Blonski JZ , Kasznicki M , et al.   Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia (Report of a prospective, randomized, multicenter trial) . Blood . 2000;96:2723–2729
  4. Anaissie EJ , Kontoyiannis DP , O’Brien S , et al.   Infections in patients with chronic lymphocytic leukemia treated with fludarabine . Ann Intern Med . 1998;129:559–566
  5. Montserrat E . Current and developing chemotherapy for CLL . Med Oncol . 2002;19(suppl):S11–S19
  6. Leporrier M , Chevret S , Cazin B , et al.   Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients . Blood . 2001;98:2319–2325
  7. Waldmann H . A personal history of the CAMPATH-1H antibody . Med Oncol . 2002;19(suppl):S3–S9
  8. Keating MJ , Flinn I , Jain V , et al.   Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine (results of a large international study) . Blood . 2002;99:3554–3561
  9. Rai KR , Keating MJ , Coutre S , et al.   Patients with refractory B-CLL and T-PLL treated with alemtuzumab (CamPath) on a compassionate basis. A report on efficacy and safety of CAM 511 trial . Blood . 2002;100:3165; (abstr)
  10. Robak T , Skotnicki AB , Mayer J , et al.   Interim safety summary of alemtuzumab vs. chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL) . J Clin Oncol . 2004;22:573s; (abstr 6563)
  11. Winkler U , Jensen M , Manzke O , et al.   Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8) . Blood . 1999;94:2217–2224
  12. Wing MG , Moreau T , Greenwood J , et al.   Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H (involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells) . J Clin Invest . 1996;98:2819–2826
  13. Lundin J , Hagberg H , Repp R , et al.   Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome . Blood . 2003;101:4267–4272
  14. Enblad G , Hagberg H , Erlanson M , et al.   A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas . Blood . 2004;103:2920–2924
  15. Rose AL , Smith BE , Maloney DG . Glucocorticoids and rituximab in vitro (Asynergistic direct antiproliferative and apoptotic effects) . Blood . 2002;100:1765–1773
  16. Lundin J , Kimby E , Bjorkholm M , et al.   Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL) . Blood . 2002;100:768–773
  17. Lundin J , Karlsson C , Kimby E , et al.   Subcutaneous alemtuzumab without dose escalation in patients with previously treated B-cell chronic lymphocytic leukemia . Leuk Lymphoma . 2005;46(suppl 1):S93; (abstr)
  18. Stilgenbauer S , Winkler D , Krober A , et al.   Subcutaneous Campath-1H (alemtuzumab) in fludarabine-refractory CLL (Interim analysis of the CLL2h study of the German CLL Study Group (GCLLSG)) . Blood . 2004;104:478; (abstr)
  19. Gilleece MH , Dexter TM . Effect of Campath-1H antibody on human hematopoietic progenitors in vitro . Blood . 1993;82:807–812
  20. Williams RJ , Clarke E , Blair A , et al.   Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G . Cytotherapy . 2000;2:5–14
  21. Osterborg A , Dyer MJ , Bunjes D , et al.  European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia   Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia . J Clin Oncol . 1997;15:1567–1574
  22. Elter T , Borchmann P , Schulz H , et al.   Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia (Results of a Phase II trial) . J Clin Oncol . 2005;23:7024–7031
  23. Keating M , Coutre S , Rai K , et al.   Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia . Clin Lymphoma . 2004;4:220–227
  24. Lundin J , Porwit MacDonald A , Rossmann ED , et al.   Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia . Leukemia . 2004;18:484–490
  25. Maloney DG , Liles TM , Czerwinski DK , et al.   Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma . Blood . 1994;84:2457–2466
  26. Perkins JG , Flynn JM , Howard RS , et al.   Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma (Implications for clinical trials in this patient population) . Cancer . 2002;94:2033–2039
  27. Wendtner C-M , Ritgen M , Schweighofer CD , et al.   Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission—Experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG) . Leukemia . 2004;18:1093–1101
  28. Montillo M , Tedschi A , Rossi V , et al.   Consolidation with alemtuzumab after a response to fludarabine in patients with CLL (confirmation of the efficacy to purge residual disease) . Leuk Lymphoma . 2005;46(suppl 1):93; (abstr)
  29. Nguyen DD , Cao TM , Dugan K , et al.   Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia . Clin Lymphoma . 2002;3:105–110
  30. Ferrajoli A , O’Brien SM , Cortes JE , et al.   Phase II study of alemtuzumab in chronic lymphoproliferative disorders . Cancer . 2003;98:773–778
  31. Cavalli-Bjorkman N , Osby E , Lundin J , et al.   Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia . Med Oncol . 2002;19:277–280
  32. Crowe JS , Hall VS , Smith MA , et al.   Humanized monoclonal antibody CAMPATH-1H (Myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material) . Clin Exp Immunol . 1992;87:105–110
  33. Isaacs JD , Watts RA , Hazleman BL , et al.   Humanised monoclonal antibody therapy for rheumatoid arthritis . Lancet . 1992;340:748–752
  34. Schnitzer TJ , Yocum DE , Michalska M , et al.   Subcutaneous administration of CAMPATH-1H (Clinical and biological outcomes) . J Rheumatol . 1997;24:1031–1036
  35. Hale G , Rebello P , Brettman LR , et al.   Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration . Blood . 2004;104:948–955

 All authors have received research grant support from Schering AG and ILEX Inc.

PII: S0093-7754(06)00059-5

doi: 10.1053/j.seminoncol.2006.01.027

Seminars in Oncology
Volume 33 , Pages 29-35 , April 2006

Article Tools

* Image Usage & Resolution